7 drug(s) with this reaction
3,737 total reports
Haemoglobin Decreased has been reported as an adverse reaction across 7 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 3,737 adverse event reports mention haemoglobin decreased in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with haemoglobin decreased, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have haemoglobin decreased listed in their FDA adverse event reports, sorted by report count:
In addition to haemoglobin decreased, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
7 drug(s) manufactured by Amgen Inc have haemoglobin decreased listed in their FDA adverse event reports: DARBEPOETIN ALFA, FILGRASTIM, EPOETIN ALFA, PEGFILGRASTIM, ROMIPLOSTIM, and others.
There are a combined 3,737 reports of haemoglobin decreased across 7 Amgen Inc drug(s) in the FDA adverse event database.